
Your daily cup of coffee could help you live longer and healthier, new study says
Want to reach older age with a sharp mind and healthy body? Part of the answer may be in your coffee cup, according to new research.
'Women who drank one to three cups of caffeinated coffee per day in their 50s were more likely to reach older age free from major chronic diseases and with good cognitive, physical, and mental health,' said lead study author Dr. Sara Mahdavi, adjunct professor in the faculty of medicine and department of nutritional sciences at the University of Toronto.
Researchers analyzed dietary data from more than 47,000 women who were part of the Nurses' Health Study, according to the research released Monday at the annual meeting of the American Society for Nutrition in Orlando. The study was presented as an abstract, but a more in-depth manuscript of the investigation will be submitted for peer review in the coming months, Mahdavi said.
The women were surveyed in middle age and followed for 30 years to understand their rates of death and disease.
'In this study, we found that moderate caffeinated coffee consumption during midlife was associated with a higher likelihood of healthy aging 30 years later,' Mahdavi said.
The effects were found in caffeinated coffee in particular, according to the research. The same link was not found for tea or decaffeinated coffee — and drinking more cola or other caffeinated sodas was tied to a lower chance of healthy aging.
'This would imply that coffee in particular has health preserving or promoting effects,' said Dr. David Kao, Jacqueline Marie Schauble Leaffer Endowed Chair in Women's Heart Disease and associate professor of medicine at the University of Colorado Anschutz Medical School in an email. 'As with other studies, they also appear to have found that coffee has a particular benefit over other caffeinated drinks.'
That said, the research is high quality, added Kao, who was not involved in the research.
The study is also observational, meaning it is limited in its ability to examine direct cause and effect. The new research can only show that a behavior and an outcome are more likely to occur together.
Researchers did take that into account and adjusted for other factors that could link coffee drinking and healthy aging such as lifestyle, demographic and other dietary differences, but it is still possible there is another variable at play, Mahdavi said.
But the link between coffee and healthy aging isn't surprising –– it is consistent with prior research, Kao said.
Moderate coffee drinking has been linked before to lower risks of chronic diseases like type 2 diabetes and cardiovascular disease, he added.
Does this mean you should take on a coffee habit if you don't have one already? Not necessarily, Mahdavi said.
'Coffee may support longevity, but it's not a universal prescription — especially for women. Hormonal shifts influence how caffeine is metabolized, so the benefits depend on timing, biology, and individual health,' she said in an email.
Estrogen inhibits a liver enzyme that is crucial for breaking down caffeine, which means that caffeine may last longer in the body of some people, especially those going through hormonal transitions such as menopause or pregnancy or those using oral contraception, Mahdavi said.
Midlife, the time period examined in this study, is a life stage marked by hormonal and metabolic shifts for women, she added.
'Moderate caffeinated coffee consumption — typically one to three cups per day — can be part of a healthy diet for many adults,' Mahdavi said. 'However, this should not be taken as a blanket recommendation for everyone to begin or increase coffee intake with the goal of longevity.'
For one thing, the data can't say whether increasing coffee consumption would help to preserve health, Kao said.
'In other words, although women who drink 3 cups of coffee/day might have better long-term functioning than non-coffee drinkers, we don't know if non-coffee drinkers started drinking 3 cups a day, whether they would have better functioning than if they remained non-coffee drinkers,' he said in an email.
The findings do suggest that people don't necessarily need to decrease their coffee consumption in the name of healthy aging, Kao said.
'Coffee is an important and positive part of daily life in many cultures around the world, he said. 'For many … the knowledge that a daily coffee or 3 is probably not harmful is welcome news.'
That said, some people do need to watch their coffee consumption, including those with high blood pressure, heart disease, anxiety and sleep disorders, said Dr. Lu Qi, HCA Regents Distinguished Chair and professor at Tulane University Celia Scott Weatherhead School of Public Health and Tropical Medicine in New Orleans.
Qi was not involved in the research but was involved in another recent study showing that having coffee in the morning had a better impact on lowering death rates than drinking it throughout the day.
Although coffee may be an enjoyable aspect of good health, it does not replace other healthy behaviors such as eating nutritious foods, exercising and getting good sleep, Mahdavi added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
UnitedHealth CFO out in latest leadership shake-up
(NewsNation) — UnitedHealth Group announced an executive swap amid a turbulent era for the company that included its CEO being killed and earnings falling below expectations. Wayne DeVeydt, most recently a managing director of Bain Capital, will become UnitedHealth's new chief financial officer on Sept. 2. John Rex, the company's current CFO, will become strategic advisor to the CEO, Stephen Hemsley. 'Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to health care that is a perfect fit for UnitedHealth Group,' Hemsley said in a release. Trump unveils medical data initiative: 'Health care into the digital age' This week, the company slashed its earnings per share expectations by nearly half while blaming soaring medical costs. In May, the company changed CEOs and withdrew its 2025 forecast altogether. The company is also dropping some Medicare Advantage plans that collectively cover more than 600,000 people. The company's revenue leapt 13% year-over-year in the second quarter, but profits sank 19%. Last month, the company also confirmed it was cooperating with the Department of Justice as it investigates aspects of its Medicare programs. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
Blue Origin's Latest Launch Sends Crypto Billionaire Justin Sun to Space After He Bid $28M for Seat on 10-Minute Flight
"When I look at it from space, Earth is so small and that's our home," Sun said after his brief trip on the New Shepard rocketNEED TO KNOW Blue Origin, founded by Jeff Bezos, brought another crew to space The crew included cryptocurrency billionaire Justin Sun, who bid $28 million for the seat on the rocket, along with five others The mission was the 34th flight for the New Shepard programSix more people have gone to space thanks to Blue Origin. The space technology company, founded by Jeff Bezos, brought another crew to space on Sunday, August, 3, including cryptocurrency billionaire Justin Sun. The mission — known as NS-34 —was the 34th flight for the New Shepard program, according to the Blue Origin website. The crew launched from West Texas on the New Shepard rocket at 8:43 a.m. local time, per Blue Origin's X. Another post confirmed that the flight controllers "confirmed capsule separation" about three minutes later, which means the crew experienced "weightlessness." "Crew Capsule apogee confirmed," Blue Origin wrote at 8:47 a.m., before confirming that the crew had "landed" mere minutes later. Another update stated that the aircraft reached touchdown at 8:53 a.m., after a total of 10 minutes. "Welcome back, NS-34 crew," the company wrote on social media. Blue Origin reported that the company "successfully completed its 14th human spaceflight" following the flight. Along with Sun, the crew included real estate investor Arvi Bahal, Turkish businessman Gökhan Erdem, meteorologist Deborah Martorell, educator Lionel Pitchford and entrepreneur J.D. Russell. Sun won a bid for his seat on the New Shepard in 2021. He bid $28 million for the seat, according to Bloomberg and The outlet reported that he was supposed to be on the landmark flight on July 20, 2021, in recognition of the 52nd anniversary of the Apollo 11 moon landing, but was unable to make the trip due to a scheduling conflict. "It was an honor to see so many nations represented on our flight today. The view of our fragile planet from space has a unifying effect on all who witness it, and I am always eager to see how our astronauts use this experience for the benefit of Earth," said Phil Joyce, Senior Vice President of Blue Origin, in a statement. Per Blue Origin's website, the New Shepard is a "fully reusable, suborbital rocket system built for human flight from the beginning." During the autonomous aircraft's 11-minute trip, those onboard pass the Kármán line into space. The crew experiences "several minutes of weightlessness and witnessing life-changing views of Earth." Singer Katy Perry, broadcast journalist Gayle King, philanthropist Lauren Sánchez, former NASA rocket scientist Aisha Bowe, bioastronautics research scientist Amanda Nguyen and film producer Kerianne Flynn notably went to space on the New Shepard in April as part of its 31st launch. Sun reflected on his brief journey into space in an interview shared on his Instagram. "For this mission, I've waited for four years but we've finally delivered it. I really appreciate Mr. Bezos and his team for making this possible. And thank you dad and mom for bringing me to Earth," he said. "When I look at it from space, Earth is so small and that's our home. We definitely need to do whatever we can do to protect it," Sun added. The entrepreneur made headlines in November 2025 for buying viral artwork depicting a yellow banana duct-taped to a wall. 'This is not just an artwork; it represents a cultural phenomenon that bridges the worlds of art, memes and the cryptocurrency community,' Sun wrote on X. 'I believe this piece will inspire more thought and discussion in the future and will become a part of history.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. "I am honored to be the proud owner of the banana 🍌 and look forward to it sparking further inspiration and impact for art enthusiasts around the world," Sun continued. He later consumed the banana used in the artwork, writing in another X post, "To be honest, for a banana with such a back story, the taste is naturally different from an ordinary one. I could discern a hint of what Big Mike bananas from 100 years ago might have tasted like." Read the original article on People Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
Key Points Hims & Hers Health is unlocking new sources of growth potential, and its balance sheet is flourishing. Doximity is a prime platform for advertisers, and the profits are pouring in. 10 stocks we like better than Hims & Hers Health › It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the industries and sectors you gravitate toward, the amount of capital you have to invest, and your own personal risk tolerance. If you have cash to invest in the stock market right now, and you're looking for growth stocks that could make smart additions to the basket of businesses you own, there are names to be found across a range of industries, including healthcare. Here are two healthcare stocks that have at least doubled over the past 12 months but still look poised to deliver favorable returns for shareholders in the next three to five years. 1. Hims & Hers Health Hims & Hers Health (NYSE: HIMS) has witnessed a stock run-up of more than 200% over the trailing-12-month period. In contrast, the S&P 500 is up only about 18% in that same time frame. This boom in the company's share price has occurred for a few reasons. Investors were particularly excited about the company's ability to offer affordable, compounded GLP-1 drugs for weight loss amid shortages of branded versions, and that fueled significant revenue growth and share-price appreciation. However, Hims & Hers can no longer mass-produce compounded drugs like semaglutide because the U.S. Food and Drug Administration declared the shortage resolved. While the company may still offer personalized doses where clinically applicable, its primary weight loss offerings are shifting to oral medications and liraglutide. In fact, Novo Nordisk, the maker of Wegovy (semaglutide for weight) and Ozempic (semaglutide for diabetes), ended its partnership with Hims & Hers, citing concerns over the latter company's promotion and sales of compounded semaglutide. While the company's offerings may evolve in the coming months and years, it has other sources of growth to lean on besides the weight loss segment. Hims & Hers' areas of focus include sexual health, hair loss, dermatology, mental health, and primary care. The platform also provides access to both over-the-counter and prescription treatments via online consultations with licensed healthcare professionals, and most of its revenue still comes from recurring subscriptions paid by healthcare consumers. The recent acquisition of Zava, a European digital health platform, seems to have boosted investor confidence in the future of the business outside of its ambitions in the weight loss industry. The addition of Zava to Hims & Hers' ecosystem will expand its reach into the U.K., Ireland, France, and Germany. Hims & Hers also plans to launch its platform in Canada in 2026. Revenue grew by 110% year over year in the first quarter, and the company is building upon an improving track record of profitability. Hims & Hers also delivered free cash flow of about $50 million in Q1. This business has a lot of potential. 2. Doximity Doximity (NYSE: DOCS) has seen shares pop by a bit more than 100% since this time one year ago. Doximity is known as the largest digital platform for U.S. medical professionals. It serves as a professional and social network for healthcare professionals including doctors, nurse practitioners, and physician assistants, and offers a wide variety of tools for communication, news, and career management. Doximity provides a curated newsfeed with the latest medical news and research relevant to different specialties, and also offers tools for job searches, salary comparisons, and reputation management. The platform even provides telehealth solutions, enabling virtual patient visits and consultations. The platform is free for healthcare professionals to use. This free access includes Doximity Dialer, a feature that allows secure communication with patients using a customized calling tool. The platform also offers free digital fax lines and access to Doximity Scribe, an AI-powered note-taking tool for verified clinicians. So, how does Doximity make money? From advertising and selling information. Doximity's platform is a prime digital marketing and advertising tool for pharmaceutical manufacturers and healthcare systems (like hospitals). These entities pay Doximity to advertise and promote their products and services to targeted medical professionals. Health systems and medical recruiting firms also pay Doximity to access its database of medical professionals for recruitment and hiring purposes. In Doximity's fiscal 2025, which ended March 31, revenue increased 20% from the prior fiscal year to $570.4 million. The company reported net income of $223.2 million, up 51% year over year, with free cash flow spiking 50% to $266.7 million. This healthcare stock is really an advertising business at its core, and a profitable one at that. These factors could induce some investors to take another long look at this top stock and I think it has room to run. Do the experts think Hims & Hers Health is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity and Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤